KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Short-Term Debt repayments (2016 - 2026)

Gsk has reported Short-Term Debt repayments over the past 18 years, most recently at -$71.5 million for Q1 2026.

  • For Q1 2026, Short-Term Debt repayments changed 0.47% year-over-year to -$71.5 million; the TTM value through Mar 2026 reached -$389.3 million, up 64.64%, while the annual FY2025 figure was -$320.6 million, 10.51% down from the prior year.
  • Short-Term Debt repayments for Q1 2026 was -$71.5 million at Gsk, up from -$99.8 million in the prior quarter.
  • Over five years, Short-Term Debt repayments peaked at -$57.1 million in Q1 2023 and troughed at -$3.1 billion in Q4 2022.
  • A 5-year average of -$500.0 million and a median of -$72.3 million in 2024 define the central range for Short-Term Debt repayments.
  • Biggest five-year swings in Short-Term Debt repayments: tumbled 892.57% in 2022 and later soared 81.95% in 2024.
  • Year by year, Short-Term Debt repayments stood at -$3.1 billion in 2022, then skyrocketed by 73.88% to -$810.5 million in 2023, then soared by 81.95% to -$146.3 million in 2024, then surged by 31.82% to -$99.8 million in 2025, then increased by 28.38% to -$71.5 million in 2026.
  • Business Quant data shows Short-Term Debt repayments for GSK at -$71.5 million in Q1 2026, -$99.8 million in Q4 2025, and -$71.8 million in Q1 2025.